Tag: GlobeNewswire

Company reaffirms fiscal 2027 adjusted EPS and local volume guidance

HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced that Brandon Sewell, the Company’s Interim Chief Financial Officer since March 2026, has been named Executive Vice President and Chief Financial Officer, effective November 1, 2026.

“Brandon has distinguished himself as a trusted and highly effective leader throughout his twelve years with the company, and when asked to step in as Interim Chief Financial Officer, he performed at a high level,” said Kevin Hourican, Sysco’s Chair of the Board and Chief Executive Officer. “Brandon commands a deep knowledge of our business, broad financial expertise, and strong understanding of how Sysco creates shareholder value. During Brandon’s interim assignment, Sysco delivered strong financial results, launched a multi-year Artificial Intelligence (AI) and Technology business modernization, and successfully financed the Jetro Restaurant Depot acquisition. With these accomplishments, Brandon has earned the trust and confidence of our leadership team, colleagues, Sysco’s board of directors and our investors.”  

“I’m honored to be appointed Chief Financial Officer and grateful for the confidence that Kevin and the Board have placed in me,” said Sewell. “Having spent more than a decade at Sysco, I have tremendous conviction in our business, our people and the opportunities ahead. I look forward to building on our strong foundation, maintaining the financial discipline that has supported our industry-leading balance sheet, and deploying our resources to advance our strategic priorities while delivering long-term value for our shareholders.”

About Brandon Sewell
Brandon Sewell has served as Interim Chief Financial Officer of Sysco since March 2026. He joined Sysco in 2014 and has held a series of finance leadership roles with increasing responsibility across the organization. Prior to being named interim CFO, Sewell served as Senior Vice President and Chief Financial Officer of Sysco’s U.S. business, the company’s largest operating segment, where he oversaw financial strategy, planning and performance management. Previously, he led Sysco’s global Financial Planning & Analysis function and held finance leadership roles across the company’s supply chain and merchandising organizations. Sewell brings more than a decade of experience at Sysco and deep knowledge of the company’s operations, financial strategy and business. Brandon has an undergraduate degree from Brigham Young University, and an MBA from Duke’s Fuqua School of Business.

In a separate press release issued today, Sysco announced its earnings results for the first quarter of fiscal 2027, confirming it remained confident in delivering on its previously stated local volume growth of approximately 2.5% and adjusted EPS growth guidance of 9%-11% for the full fiscal year.

Forward-Looking Statements

Statements made in this press release or in our earnings call for the first quarter of fiscal year 2027 that look forward in time or that express management’s beliefs, expectations or hopes are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements concern, among other things, our future financial performance and results, business strategy, plans, goals and objectives, including certain outlook, business trends, our dividend and share repurchase programs, our expectation of future macroeconomic conditions and other statements that are not historical facts, including our expectations regarding foot traffic and volume growth and benefits to gross margins; our expectations regarding our future growth, including growth in sales and earnings per share; and our expectations regarding cost savings associated with AI, as well as statements about the expected timing and completion of the proposed transaction with Jetro Restaurant Depot and the anticipated benefits of such proposed transaction, including estimated synergies, and plans, impact on Sysco and expectations for Sysco after completion of the proposed transaction.

Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions, including those outside of Sysco’s control. Risks and uncertainties include without limitation: the impact of geopolitical, economic and market conditions and developments, including changes in global trade policies and tariffs and foreign conflicts; risks related to our business initiatives; periods of significant or prolonged inflation or deflation and their impact on our product costs, volume, foot traffic, and profitability generally; risks related to our efforts to implement our transformation initiatives and meet our other long-term strategic objectives; risk of interruption of supplies and increase in product costs; risks related to changes in consumer eating habits; and impact of natural disasters or adverse weather conditions, public health crises, adverse publicity or lack of confidence in our products, and product liability claims as well as risks and uncertainties associated with our proposed transaction with Jetro Restaurant Depot, including but not limited to, the occurrence of any event, change or other circumstances that could give rise to the right of either or both parties to terminate the merger agreement; the risk that regulatory approvals may not be obtained or other closing conditions may not be satisfied in a timely manner or at all, as well as the risk that regulatory approvals are obtained subject to conditions that are not anticipated; the risk of other delays in closing the transaction; the possibility that any of the anticipated benefits and projected synergies of the transaction will not be realized or will not be realized within the expected time period; and the risk that the proposed transaction and its announcement could have an adverse effect on the market price of the common stock of Sysco. Should one or more of these risks or uncertainties materialize, or underlying assumptions prove incorrect, actual results may vary materially from those indicated in our forward-looking statements. Therefore, you should not place undue reliance on any of the forward-looking statements contained herein. For more information on these risks and other concerning factors that could cause actual results to differ from those expressed or forecasted, see our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC. We do not undertake to update our forward-looking statements, except as required by applicable law.

About Sysco

Sysco is the global leader in selling, marketing and distributing food and related products to customers who prepare meals away from home. This includes restaurants, healthcare and educational facilities, lodging establishments, entertainment venues, and more. Sysco operates 333 distribution centers, in 10 countries, with 75,000 colleagues serving approximately 670,000 customer locations. The company generated sales of more than $84 billion in fiscal year 2026 that ended June 27, 2026.

As the world’s largest food-away-from-home distributor, Sysco offers customized supply chain solutions, bespoke specialty product offerings, and culinary support to drive customers to innovate and optimize their operations. We act as a trusted business partner to our customers, helping them grow through our industry-leading portfolio that includes fresh produce, premium proteins, specialty products, sustainably focused items, equipment and supplies, and innovative culinary solutions.

For more information, visit www.sysco.com. For important news and key information for Sysco investors, visit the Investor Relations section of the company’s website at investors.sysco.com.

For more information contact:
Kevin Kim	Cassandra Mauel
Investor Contact	Media Contact
kevin.kim@sysco.com	cassandra.mauel@sysco.com
T 281-584-1219	T 281-584-1390

SYY-INVESTORS

Recognition highlights TransUnion’s strength across employee experience, financial performance and sustainability transparency

CHICAGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced it has been named to TIME’s America’s Best Companies 2026 list, a recognition that identifies the top-performing companies in the United States based on employee satisfaction, financial performance and sustainability transparency.

TransUnion helps enable trust between consumers and businesses in areas such as credit, fraud prevention, marketing and consumer solutions. Decades of responsible data stewardship and continued investment in technology and innovation have allowed the company to expand beyond traditional credit reporting while maintaining a strong focus on ensuring consumers and organizations transact with confidence and achieve great things.

TransUnion’s purpose, Information for Good^®, guides its efforts to help people access opportunities that can lead to a higher quality of life. Through its products, solutions and responsible business practices, TransUnion works to expand financial inclusion, strengthen trust in the marketplace and help consumers participate more fully in the global economy.

This commitment is also reflected in how TransUnion operates with honesty, trust and respect across its business. The company continues to strengthen responsible data and AI governance, helps organizations deliver safe and relevant experiences for consumers, and aims to create positive impact in the world throughout its value chain. That same commitment shapes the associate experience, fostering a supportive and collaborative environment where teams can contribute, grow and thrive.

“At TransUnion, responsible growth and long-term value creation go hand in hand,” said Chris Cartwright, President and CEO of TransUnion. “This recognition celebrates how we deliver strong performance while operating responsibly and creating impactful experiences for our associates, customers and consumers.”

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good^® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.
http://www.transunion.com/business

Contact	Dave Blumberg
Email	david.blumberg@transunion.com
Telephone	312-972-6646

Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial and Advanced Solutions

Focused on Driving Margin Expansion

MARLBOROUGH, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2026.

		Three Months Ended September 30,											Nine Months Ended September 30,
(In millions, except per share data and percentages)			2026				2025			Change				2026				2025			Change
Revenue		$	287.5			$	250.8			15	%		$	831.6			$	729.3			14	%
Gross margin			40.7	%			39.5	%						39.6	%			38.7	%
Operating income		$	20.8			$	7.9			NM			$	17.6			$	9.8			NM
Operating margin			7.2	%			3.1	%						2.1	%			1.3	%
Net income		$	20.3			$	7.5			171	%		$	27.1			$	17.8			52	%
Earnings per diluted share		$	0.47			$	0.18			161	%		$	0.63			$	0.42			50	%
Non-GAAP Measures*
Adjusted gross margin			41.0	%			39.8	%						39.9	%			39.2	%
Adjusted EBITDA		$	51.5			$	37.0			39	%		$	135.2			$	101.2			34	%
Adjusted earnings per diluted share		$	0.61			$	0.35			74	%		$	1.49			$	0.96			55	%

*Adjusted gross margin, adjusted EBITDA and adjusted earnings per diluted share include non-GAAP adjustments. A reconciliation from GAAP to non-GAAP metrics is provided in this earnings release.

NM – not meaningful.

Management Comments
“We delivered our fourth consecutive quarter of double-digit year-over-year revenue growth, with revenue above the midpoint of our guidance,” said Dr. Mark Gitin, Chief Executive Officer of IPG Photonics. “Our performance reflects the strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets. Strong demand for our differentiated welding and additive manufacturing solutions drove growth in Industrial Solutions while disciplined execution of our key strategic initiatives across defense and semiconductor markets led to strong growth in Advanced Solutions. Additionally, I anticipate that our acquisition of Lumibird Medical, which is expected to close in the fourth quarter, will further strengthen our reach, accelerate growth across medical markets, and increase revenue in Advanced Solutions.”

Financial Highlights

	Three Months Ended September 30,									Nine Months Ended September 30,
		2026			2025		Change				2026			2025		Change
Sales by Application
Industrial Solutions	$	239,548		$	214,697		12	%		$	704,181		$	607,593		16	%
Advanced Solutions		47,952			36,095		33	%			127,396			121,713		5	%
Total	$	287,500		$	250,792		15	%		$	831,577		$	729,306		14	%

Third quarter revenue of $288 million increased 15% year over year, driven by 12% growth in Industrial Solutions and 33% growth in Advanced Solutions. Changes in foreign exchange rates increased revenue by approximately 1%. Industrial Solutions sales, accounting for 83% of total revenue, were driven by strong performance in welding and additive manufacturing applications. Advanced Solutions sales improved, driven by higher sales in semiconductor and defense applications. Emerging growth products accounted for 52% of total revenue, down from 58% in the prior quarter due to product mix. By region, sales increased 14% in Asia and 33% in North America and decreased 1% in Europe on a year-over-year basis.

GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year over year, driven by lower product costs and $5.0 million in net tariff refunds recorded in the period, partially offset by lower fixed cost absorption. Net income was $20 million, or $0.47 per diluted share, and adjusted EBITDA was $52 million and adjusted earnings per diluted share (EPS) was $0.61 in the third quarter. During the third quarter, IPG generated $46 million in cash flow from operations and spent $17 million on capital expenditures.

Business Outlook and Financial Guidance

“Our third quarter book-to-bill was approximately one as we continued to see improved industrial demand and executed on our strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers. As we move forward, we remain focused on driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio,” concluded Dr. Gitin.

For the fourth quarter of 2026, IPG expects revenue of $265 million to $295 million, adjusted gross margin between 37.0% and 40.0% and adjusted operating expenses of $91 million to $94 million. IPG anticipates delivering adjusted earnings per diluted share in the range of $0.30 to $0.60 and adjusted EBITDA in the range of $33 million to $50 million. The guidance assumes no contribution from the acquisition of Lumibird Medical.

As discussed in more detail in the “Safe Harbor” passage of this news release, actual results may differ from this guidance due to various factors including, but not limited to, trade policy changes and trade restrictions, product demand, order cancellations and delays, competition, tariffs and retaliatory tariffs, currency fluctuations and general economic conditions. The current uncertainty related to the trade environment and tariff policies increases the risks to the outlook that we have provided. This guidance is based upon current market conditions and expectations and is subject to the risks outlined in the Company’s reports filed with the SEC and assumes exchange rates relative to the U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.

Supplemental Financial Information

Additional supplemental financial information is provided in the unaudited Financial Data Workbook and Third Quarter 2026 Earnings Call Presentation available on the investor relations section of the Company’s website at investor.ipgphotonics.com.

Conference Call Reminder

The Company will hold a conference call today, November 3, 2026 at 10:00 am ET. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the Company’s website at investor.ipgphotonics.com.

Contact

Eugene Fedotoff
Senior Director, Investor Relations
IPG Photonics Corporation
508-597-4713
efedotoff@ipgphotonics.com

About IPG Photonics Corporation

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible. Discover more at www.ipgphotonics.com.

Safe Harbor Statement
Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including those statements related to strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets, the expected timing of the closing of our acquisition of Lumibird Medical and the expectation that the acquisition will increase revenue in Advanced Solutions and strengthen our reach and accelerate growth across medical markets, strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers, driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio, revenue, adjusted gross margin and adjusted operating expenses outlook, adjusted earnings per diluted share and adjusted EBITDA guidance, including the expected impact of tariffs, and the impact of the U.S. dollar on our guidance for the fourth quarter of 2026. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; inability to manage risks associated with international customers and operations; changes in trade controls and tariff policies; IPG’s ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG’s products; foreign currency fluctuations; high levels of fixed costs from IPG’s vertical integration; the appropriateness of IPG’s manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG’s SEC filings. Readers are encouraged to refer to the risk factors described in IPG’s Annual Report on Form 10-K (filed with the SEC for the fiscal year ended December 31, 2025), IPG’s Quarterly Report on Form 10-Q (filed with the SEC for the quarter ended June 30, 2026), and other reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

IPG PHOTONICS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
		Three Months Ended September 30,							Nine Months Ended September 30,
			2026				2025			2026			2025
		(In thousands, except per share data)
Net sales		$	287,500			$	250,792		$	831,577		$	729,306
Cost of sales			170,446				151,787			502,500			446,916
Gross profit			117,054				99,005			329,077			282,390
Operating expenses:
Sales and marketing			23,934				23,771			72,286			73,753
Research and development			31,335				30,358			95,648			88,631
General and administrative			37,502				35,092			110,139			102,782
Settlement of litigation matters			—				—			13,334			—
Impairment charges			231				—			17,805			—
Restructuring charges			—				425			—			425
Loss on foreign exchange			3,275				1,504			2,293			7,013
Total operating expenses			96,277				91,150			311,505			272,604
Operating income			20,777				7,855			17,572			9,786
Other income, net:
Interest income, net			7,688				7,283			21,720			22,728
Other (expense) income, net			(50	)			516			2,683			2,026
Total other income			7,638				7,799			24,403			24,754
Income before provision for income taxes			28,415				15,654			41,975			34,540
Provision for income taxes			8,142				8,191			14,876			16,714
Net income		$	20,273			$	7,463		$	27,099		$	17,826
Net income per common share:
Basic		$	0.48			$	0.18		$	0.64		$	0.42
Diluted		$	0.47			$	0.18		$	0.63		$	0.42
Weighted average common shares outstanding:
Basic			42,531				42,199			42,416			42,427
Diluted			42,840				42,556			42,904			42,659

IPG PHOTONICS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
		September 30,				December 31,
			2026				2025
		(In thousands, except share data)
ASSETS
Current assets:
Cash and cash equivalents		$	710,688			$	403,790
Short-term investments			215,304				435,538
Accounts receivable, net			191,150				181,734
Inventories			337,890				313,416
Prepaid income taxes			33,145				43,196
Prepaid expenses and other current assets			54,460				45,766
Total current assets			1,542,637				1,423,440
Long-term investments			—				76,533
Deferred income taxes, net			122,235				123,889
Goodwill			70,281				71,735
Intangible assets, net			42,777				49,933
Property, plant and equipment, net			648,326				637,516
Other assets			45,787				41,234
Total assets		$	2,472,043			$	2,424,280
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable		$	48,782			$	39,288
Accrued expenses and other current liabilities			204,874				184,849
Income taxes payable			3,858				9,900
Total current liabilities			257,514				234,037
Other long-term liabilities and deferred income taxes			59,581				62,113
Total liabilities			317,095				296,150
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value, 175,000,000 shares authorized; 57,380,668 and 42,508,140 shares issued and outstanding, respectively, at September 30, 2026; 56,964,939 and 42,127,067 shares issued and outstanding, respectively, at December 31, 2025.			6				6
Treasury stock, at cost, 14,872,528 and 14,837,872 shares held at September 30, 2026 and December 31, 2025, respectively.			(1,558,277	)			(1,555,629	)
Additional paid-in capital			1,097,673				1,077,172
Retained earnings			2,672,063				2,644,964
Accumulated other comprehensive loss			(56,517	)			(38,383	)
Total stockholders’ equity			2,154,948				2,128,130
Total liabilities and stockholders’ equity		$	2,472,043			$	2,424,280

IPG PHOTONICS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
		Nine Months Ended September 30,
			2026				2025
		(In thousands)
Cash flows from operating activities:
Net income		$	27,099			$	17,826
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			47,377				46,799
Impairment charges			17,805				—
Provisions for inventory, warranty & bad debt			33,594				31,766
Other			25,081				21,119
Changes in assets and liabilities that provided (used) cash:
Accounts receivable and accounts payable			1,535				18,787
Inventories			(60,189	)			(52,005	)
Other			(13,771	)			(37,757	)
Net cash provided by operating activities			78,531				46,535
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment			(54,437	)			(60,907	)
Proceeds from sales of property, plant and equipment			2,204				605
Purchases of investments			(360,732	)			(866,402	)
Purchases of equity investment			(8,000	)			—
Proceeds from maturities of investments			663,124				633,731
Deposit received from buyer for assets held for sale			2,000				—
Other			111				69
Net cash provided by (used in) investing activities			244,270				(292,904	)
Cash flows from financing activities:
Payments for taxes related to net share settlement of equity awards less proceeds from issuance of common stock under employee stock option and purchase plans			(11,053	)			(4,316	)
Purchase of treasury stock net of excise tax, at cost			(2,648	)			(46,603	)
Net cash used in financing activities			(13,701	)			(50,919	)
Effect of changes in exchange rates on cash, cash equivalents and cash held for sale			(1,727	)			23,274
Net increase (decrease) in cash, cash equivalents and cash held for sale			307,373				(274,014	)
Cash and cash equivalents — Beginning of period			403,790				620,040
Cash, cash equivalents and cash held for sale — End of period		$	711,163			$	346,026
Supplemental disclosures of cash flow information:
Cash paid for interest		$	54			$	136
Cash paid for income taxes, net of refunds		$	9,273			$	44,258
IPG PHOTONICS CORPORATION SUPPLEMENTAL SCHEDULE OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)

Use of Non-GAAP Adjusted Financial Information

We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”) and are provided as supplemental information to enhance understanding of the Company’s financial performance. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measure presented by the Company. The following information provides the definition of adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted net earnings per share (EPS), and adjusted tax rate as presented, which are financial measures that are not calculated or presented in accordance with GAAP, and reconciliation to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and an adjusted tax rate as supplemental information and in addition to the financial measures presented by the Company that are calculated and presented in accordance with GAAP.

We define adjusted gross profit as reported gross profit, adjusted for non-recurring, infrequent, or unusual charges, including acquisition and integration charges and amortization of acquisition-related intangibles.

We define adjusted gross margin as adjusted gross profit divided by total revenue.

We define adjusted operating expense and resultant adjusted operating income as reported operating expenses and resultant operating income, adjusted for non-recurring, infrequent, or unusual charges, including impairment charges, settlement and fees of litigation matters, restructuring charges, acquisition and integration charges, amortization of acquisition-related intangibles, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.

We define EBITDA as net income plus interest expense (income), provision for income taxes, depreciation expense, and amortization expense.

We define adjusted EBITDA as EBITDA adjusted for non-recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including stock-based compensation, restructuring charges, impairment charges, settlement and fees of litigation matters, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.

We define adjusted net income as reported net income, adjusted for non-recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including impairment charges, settlement and fees of litigation matters, restructuring charges, amortization of acquisition-related intangibles, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture, certain discrete tax items and non-GAAP income tax reconciling adjustments.

We define adjusted EPS as adjusted net income divided by the weighted-average diluted shares outstanding.

We define adjusted tax rate as the GAAP tax rate, adjusted for discrete tax items and the net impact of non-GAAP adjustments.

Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. Specifically, these non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts.

In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. However, these non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies. Management may, however, utilize other measures to illustrate performance in the future. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP measures has been provided below. These non-GAAP measures exclude (i) amortization of acquisition-related intangibles, (ii) restructuring charges, (iii) acquisition and integration costs, (iv) impairment charges, (v) foreign exchange gains/losses, (vi) interest income, (vii) benefit (provision) from income taxes, (viii) depreciation, (ix) amortization, (x) stock-based compensation, (xi) gain/loss on disposal of assets/divestiture, (xii) settlement and fees of litigation matters, (xiii) certain discrete tax items, and (xiv) non-GAAP income tax reconciling adjustments.

We have not provided a quantitative reconciliation of forward-looking Non-GAAP adjusted earnings per diluted share and adjusted EBITDA to their most directly comparable GAAP financial measures because we are unable to estimate with reasonable certainty the ultimate timing or amount of certain significant items without unreasonable efforts. This is due to the inherent difficulty of forecasting the timing and/or amount of various items that would impact adjusted earnings per diluted share and adjusted EBITDA. This includes items that have not yet occurred, are out of the Company’s control, cannot be reasonably predicted and/or for which there would not be any meaningful adjustment or difference. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Our non-GAAP tax provision for the fiscal third quarter of 2026 is 23%. The difference between our GAAP income tax provision and our non-GAAP income tax provision is presented as non-GAAP income tax reconciling adjustments.

IPG PHOTONICS CORPORATION SUPPLEMENTAL SCHEDULE OF NON-GAAP MEASURES (UNAUDITED)
Reconciliation of Gross Profit to Adjusted Gross Profit, Adjusted Gross Margin
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
		(in thousands, except percentages)
Gross profit		$	117,054			$	99,005			$	329,077			$	282,390
Gross margin			40.7	%			39.5	%			39.6	%			38.7	%
Amortization of acquisition-related intangibles			720				851				2,360				2,928
Acquisition and integration charges			—				—				—				482
Adjusted gross profit		$	117,774			$	99,856			$	331,437			$	285,800
Adjusted gross margin			41.0	%			39.8	%			39.9	%			39.2	%

Reconciliation of Operating Expenses to Adjusted Operating Expenses

		Three Months Ended September 30,						Nine Months Ended September 30,
			2026			2025			2026			2025
		(in thousands)
Operating expenses		$	96,277		$	91,150		$	311,505		$	272,604
Less:
Amortization of acquisition-related intangibles			1,231			1,551			3,701			4,570
Acquisition and integration charges			151			246			987			1,823
Impairment charges			231			—			17,805			—
Restructuring charges			149			425			500			425
Settlement and fees of litigation matters			—			—			14,435			—
Loss on foreign exchange			3,275			1,504			2,293			7,013
Adjusted operating expenses		$	91,240		$	87,424		$	271,784		$	258,773

Reconciliation of Operating Income to Adjusted Operating Income

		Three Months Ended September 30,						Nine Months Ended September 30,
			2026			2025			2026			2025
		(in thousands)
Operating income		$	20,777		$	7,855		$	17,572		$	9,786
Amortization of acquisition-related intangibles			1,951			2,402			6,061			7,498
Acquisition and integration charges			151			246			987			2,305
Impairment charges			231			—			17,805			—
Restructuring charges			149			425			500			425
Settlement and fees of litigation matters			—			—			14,435			—
Loss on foreign exchange			3,275			1,504			2,293			7,013
Adjusted operating income		$	26,534		$	12,432		$	59,653		$	27,027

Reconciliation of Net income to Adjusted EBITDA

		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
		(in thousands)
Net income		$	20,273			$	7,463			$	27,099			$	17,826
Interest income, net			(7,688	)			(7,283	)			(21,720	)			(22,728	)
Provision for income taxes			8,142				8,191				14,876				16,714
Depreciation			12,986				12,392				38,447				36,120
Amortization			2,976				3,240				8,930				10,679
EBITDA		$	36,689			$	24,003			$	67,632			$	58,611
Impairment charges			231				—				17,805				—
Stock based compensation			11,022				10,780				31,597				32,834
Restructuring charges			149				425				500				425
Acquisition and integration charges			151				246				987				2,305
Settlement and fees of litigation matters			—				—				14,435				—
Loss on foreign exchange			3,275				1,504				2,293				7,013
Adjusted EBITDA		$	51,517			$	36,958			$	135,249			$	101,188

Reconciliation of GAAP to Non-GAAP Net Income, and GAAP to Non-GAAP Net Income per Share, Diluted

		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
		(in thousands, except per share data)
Net income		$	20,273			$	7,463			$	27,099			$	17,826
Impairment charges			231				—				17,805				—
Amortization of acquisition-related intangibles			1,951				2,402				6,061				7,498
Restructuring charges			149				425				500				425
Acquisition and integration charges			151				246				987				2,305
Settlement and fees of litigation matters			—				—				14,435				—
Loss on foreign exchange			3,275				1,504				2,293				7,013
Certain discrete tax items			949				3,414				84				8,303
Tax impact of non-GAAP adjustments			(711	)			(613	)			(5,337	)			(2,471	)
Adjusted net income		$	26,268			$	14,841			$	63,927			$	40,899
Adjusted net earnings per diluted share		$	0.61			$	0.35			$	1.49			$	0.96
Weighted average diluted shares outstanding			42,840				42,556				42,904				42,659

Reconciliation of GAAP to Non-GAAP Effective Tax Rate

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Tax rate		29		%		52		%		35		%		48		%
Discrete tax items		(3	)	%		(22	)	%		—		%		(24	)	%
Net impact of non-GAAP adjustments		(3	)	%		(3	)	%		(11	)	%		(3	)	%
Adjusted tax rate		23		%		27		%		24		%		21		%

NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

• Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 4:00 p.m. ET on Tuesday, November 10.
• Stifel 2026 Healthcare Conference in New York, NY on Wednesday, November 11, 2026. Michael Davidson, M.D., Chief Executive Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:20 a.m. ET on Wednesday, November 11.
• Jefferies Global Healthcare Conference in London, UK on Wednesday, November 18, 2026. John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 11:30 a.m. GMT on Wednesday, November 18.

Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities 3^rd Annual Healthcare Innovation Conference, to take place November 9-11, 2026.

Presentation Details

Date / Time:	November 10, 2026, at 11:30 AM ET
Format:	Fireside chat and 1×1 investor meetings
Location:	Boston, MA
Webcast Link:	here

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is approved for adult patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026:

Guggenheim 3rd Annual Healthcare Innovation Conference – Boston
Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET

Stifel 2026 Healthcare Conference – New York
Fireside chat on Wednesday, November 11, 2026, at 1:20 p.m. ET

UBS Global Biopharma Conference – London
Fireside chat on Monday, November 16, 2026, at 2:00 p.m. GMT

9th Annual Evercore Healthcare Conference – Miami
Fireside chat on Tuesday, December 1, 2026, at 7:55 a.m. ET

A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform^® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

Project will integrate solar, battery storage, and on-site generation to strengthen mission readiness amid grid outages and other disruptions

LOUISVILLE, Ky. and NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, in coordination with joint venture partner AACON General Contractors, today announced that AACON-RavenVolt JV, LLC has been awarded a construction contract by the U.S. Army Corps of Engineers (USACE) Louisville District to construct an advanced microgrid at White Sands Missile Range in New Mexico. RavenVolt is ABM’s energy solutions subsidiary.

Awarded under the Department of Defense’s Energy Resilience and Conservation Investment Program (ERCIP), the project will combine solar power, battery energy storage, on-site backup generation, and advanced controls to safeguard mission-critical military operations against external grid outages, extreme weather events, and other power disruptions.

“Reliable power is fundamental to mission readiness, and critical military installations require robust, modern infrastructure to guarantee continuous operation,” said Mark Hawkinson, President, Engineering & Infrastructure Solutions, ABM. “Through the combined strengths of AACON General Contractors and RavenVolt, the AACON-RavenVolt joint venture is proud to partner with the U.S. Army Corps of Engineers Louisville District to deliver a resilient power system engineered to sustain White Sands Missile Range when the commercial grid cannot.”

Constructed under a Design-Bid-Build framework, the secure feeder-level microgrid will integrate a carport-mounted solar photovoltaic (PV) array, a high-capacity battery energy storage system (BESS), dispatchable on-site generators, and an intelligent microgrid control system. Working as a single, coordinated system, these distributed energy assets will allow the installation to seamlessly island, reduce dependence on the local utility grid, and provide redundant power to vital cantonment area facilities. The scope also includes new electrical distribution lines, fiber optic communications, and security infrastructure.

The White Sands Missile Range award demonstrates AACON-RavenVolt JV, LLC’s specialized capability in delivering complex federal energy resilience and mission-critical infrastructure projects.

About AACON-RavenVolt JV, LLC
AACON-RavenVolt JV, LLC is a Small Business joint venture combining the federal general contracting experience of AACON General Contractors (Louisville, KY) with the turnkey microgrid and distributed energy engineering expertise of RavenVolt, a subsidiary of ABM. The partnership provides federal agencies with dependable, end-to-end energy resilience and infrastructure construction capabilities.

About ABM
ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and more efficient, enhancing the overall occupant experience. ABM serves a wide range of market sectors including commercial real estate, aviation, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.

For more information, visit www.abm.com.

MEDIA CONTACT: 
Michael Valentino 
ABM 
media@abm.com  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e071d9b9-a270-48ff-9558-b0655193742c

Board of Directors authorizes repurchase of up to $30 million of the Company’s common stock

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) — XMax Inc. (NASDAQ: XMAX) (“XMax” or the “Company”), a distributor of contemporary furniture and artificial intelligence software and platform-based service provider, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million in aggregate purchase price of its outstanding common stock, par value $0.001 per share. Shares may be repurchased only at prices below $5.50 per share.

The program will begin on a date to be determined (the “Commencement Date”) after the Company has (i) publicly released its financial results for the fiscal quarter ended September 30, 2026 by press release (“Earnings Release”), (ii) publicly disclosed any material nonpublic information, and (iii) engaged a broker-dealer for the program. No repurchases will be made before the Commencement Date, and the program will expire three months after it.

Repurchases are expected to be made from time to time through open-market purchases, which may include purchases under a trading plan intended to satisfy Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to be made in accordance with Rule 10b-18 under the Exchange Act and other applicable legal requirements.

The timing, manner, price (subject to the $5.50 per share limit) and amount of any repurchases will be determined by the Company’s management based on its evaluation of market conditions, the trading price of the Company’s common stock, liquidity and capital requirements, legal requirements, and other factors. The program does not obligate the Company to repurchase any particular number of shares, and it may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund repurchases with its existing cash and cash equivalents.

“The Board’s authorization of this share repurchase program reflects our confidence in XMax’s long-term strategy and our commitment to creating value for shareholders,” said Andy Lu, Chief Executive Officer of XMax. “As we continue to develop our artificial intelligence software and platform-based services alongside our contemporary furniture business, we intend to take a disciplined approach to capital allocation, balancing investment in the growth of the business with returns to our shareholders.”

About XMax Inc.

Headquartered in Commerce, California, XMax Inc. (NASDAQ: XMAX), formerly known as Nova LifeStyle, Inc., is a diversified company engaged in the design, sourcing, and distribution of contemporary furniture, as well as the development of artificial intelligence technologies and applications. The Company operates through an established global network of suppliers, distributors, and e-commerce channels, serving a broad customer base. The Company has expanded into artificial intelligence technologies, including AI software and platform-based services through its wholly owned subsidiaries XMax AI Inc. and Elonx AI Holdings PTE. LTD., to support future growth. By leveraging emerging technologies, the Company aims to drive diversification and long-term value creation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the share repurchase program, the expected timing of its commencement and of the Earnings Release, and the manner, timing, amount and funding of any repurchases. These statements are based on current expectations, assumptions and analyses made by us in light of our experience and our perception of trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances, and are subject to risks and uncertainties that may cause actual results to differ materially, including changes in the trading price of the Company’s common stock, market conditions, the Company’s financial condition, liquidity and capital requirements, legal and regulatory requirements, and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory,” “focus,” “work to,” “attempt,” “pursue,” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. XMax Inc. undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations Contact

ICR LLC
XMaxIR@icrinc.com

Nuclear News’ recognition highlights Waples’ technical leadership and contributions to advancing innovative nuclear waste disposal solutions

PLANO, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced that Matt Waples, the Company’s Director of Engineering, has been named to Nuclear News’ 2026 “40 Under 40” list, recognizing emerging leaders whose technical expertise and innovation are helping shape the future of the nuclear industry. Published by the American Nuclear Society, Nuclear News’ annual “40 Under 40” program celebrates young professionals making meaningful contributions to nuclear science, technology, and industry advancement.

“Matt exemplifies the technical excellence and leadership needed to address one of the nuclear industry’s most important challenges,” said Rod Baltzer, CEO of Deep Isolation. “His ability to translate complex engineering challenges into practical solutions has been instrumental to our progress. We are incredibly proud to see his contributions recognized among the next generation of nuclear industry leaders.”

“It is an honor to be recognized alongside so many talented professionals working to advance nuclear energy,” said Waples. “Developing practical solutions for nuclear waste disposal requires collaboration, rigorous engineering and a commitment to long-term safety. I am proud to be part of a team helping move these technologies toward real-world application.”

Since joining Deep Isolation in 2022, Matt Waples has played a central role in advancing the Company’s deep borehole disposal technology, bringing expertise across engineering design, regulatory analysis, safety, operations and project management. His contributions have supported key research and development initiatives aimed at establishing practical, scalable pathways for the long-term disposal of spent nuclear fuel and high-level radioactive waste.

Waples played a key role in Deep Isolation’s U.S. Department of Energy-funded ARPA-E UPWARDS project, leading regulatory analysis and waste acceptance criteria development. His leadership extends to the ARPA-E SAVANT project, where his work on disposal canister materials and supply chains contributed to a paper receiving a “Superior” recognition at the 2025 Waste Management Symposia. Waples has also supported international initiatives and collaborative research through the International Atomic Energy Agency and the OECD Nuclear Energy Agency’s WISARD project.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution is designed to offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: https://www.deepisolation.com

Media Contact
Sophie McCallum
media@deepisolation.com

Investor Contact
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards; our failure to manage our growth effectively or to execute our business plan; a failure to sustain and expand relationships with governmental entities and strategic partners; failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. ”

Additional information concerning the factors above and other factors can be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026, subsequent quarterly reports on Form 10-Q filed with the SEC, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation Nuclear at InvestorRelations@deepisolation.com.

Naples, Italy and Hamilton, Bermuda, Nov. 03, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced a landmark moment for Savoia, which has advanced to the quarter-finals of the Coppa Italia for the first time in its 118-year history. Goals from Pasquale Riccardi and Matteo Polizzi secured a 2-0 victory over Sorrento at home on October 27, delivering a significant milestone for the Club. The Coppa Italia is an annual Italian domestic knock out competition played by 60 teams. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Three Matches, Three Wins

The achievement was built one round at a time. Savoia began with a 2-1 win away at Casertana on August 14, followed by a 3-0 win away at Catania on September 2, before the decisive evening against Sorrento at home. Across the three matches, the Club scored seven goals and conceded only one.

Next Up: The Defending Champs

The quarter-final brings a prestigious test: on December 8, Savoia travels to face defending champions and current cup holder Potenza. The Club views the fixture as a further source of pride and an incentive to keep improving.

October in the League

The cup success crowned a month that was also encouraging in the Serie C league. Savoia drew 0-0 away at Monopoli on October 3, defeated Inter U23 2-1 on October 10, and drew 1-1 with Cosenza on October 24, collecting valuable points along the way. The month’s only setback was a 4-0 defeat to Cerignola on October 18.

Savoia defeated Sorrento 2-0 at home.

History is Made and the Work Continues

“Reaching the quarter-finals of the Coppa Italia for the first time is an emotional moment that we share with the entire Savoia family. For 118 years, generations of supporters have cherished these colors and passed their passion down through their families. Adding a new chapter to that history fills us with pride and brings a great sense of responsibility. Credit goes to the players, the coaching staff and everyone who works on this project every day. We dedicate this historic achievement to our supporters, with the ambition of giving them even more to celebrate. October also leaves us with a positive league record. The victory over Inter U23 and the draws against Monopoli and Cosenza are important results; the defeat at Cerignola remains a match we must learn from. We are fully on track with our plan and continue to work with confidence, humility and ambition. Achieving this historic milestone gives us even greater motivation to keep moving forward.”

• General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company’s three mobile games in development include Regalia Cards (card game), Palazzo Chronicles (match-3 castle and garden-building game) and Viva Verdi (trading card game). The Company is also actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• THE ROYALAND COMPANY LTD.